CSIQ Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Canadian Solar Inc (CSIQ) is not a good buy for a beginner investor with a long-term strategy at this time. The company's financial performance has been weak, with significant declines in revenue, net income, and gross margin. The technical indicators are bearish, and the stock has been downgraded by multiple analysts with reduced price targets. While there are long-term growth catalysts such as U.S. manufacturing expansion and a $3.6 billion storage backlog, the near-term outlook is clouded by weak guidance, project delays, and higher input costs. Given the investor's profile and the current state of the stock, holding off on investment is recommended.
The technical indicators for CSIQ are bearish. The MACD histogram is negative and contracting, RSI is neutral at 33.392, and moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading near its key support level of 13.307, with resistance levels at 15.825 and 18.342.
Strategic shift towards U.S. manufacturing, which could position the company well for long-term growth.
$3.6 billion storage backlog, indicating potential future revenue streams.
Freedom Capital upgraded the stock to Buy, citing long-term potential.
Weak Q4 financial performance, with revenue down 20% YoY and a significant net loss.
Lowered guidance for Q1 and deferred 2026 shipment guidance.
Multiple analysts downgraded the stock and reduced price targets, citing challenges like higher input costs and project delays.
Bearish technical indicators and a declining stock price.
In Q4 2025, Canadian Solar reported a 19.99% YoY decline in revenue to $1.217 billion, a net loss of $86.34 million (down 354.66% YoY), and a gross margin decline to 10.22% (down 28.38% YoY). EPS fell to -1.28, a 356% YoY decrease.
Analyst sentiment is mixed but leans negative. Freedom Capital upgraded the stock to Buy with a price target of $16, citing long-term potential. However, other firms like Goldman Sachs, Mizuho, and Roth Capital lowered their price targets to $11-$15, citing weak Q4 performance, lower guidance, and higher costs. Oppenheimer remains optimistic with a $19 price target, citing structural changes and U.S. manufacturing expansion.
